To further validate the correlation between tumor MTAP loss and sensitivity to antifolate agents, we took advantage of the BATTLE-2 trial34 that enrolled patients with metastatic nonsmall cell lung cancer, some of which were treated with pemetrexed-containing chemotherapy. This evidence concerns the gene MTAP and neoplasm.